Skip to Main Content
Try STAT+ TODAY
Trending:
STAT+
Health
Biotech
First Opinion
The Readout

Dubious cancer drugs, patent battle heats up, & a better microscope

  • Damian Garde
  • Meghana Keshavan

By Damian Garde and Meghana Keshavan Oct. 6, 2017

Reprints
The READOUT
Alex Hogan/STAT

The Readout for October 06, 2017

About the Authors Reprints

Damian Garde

Damian Garde

National Biotech Reporter

Damian Garde covers biotech, is a co-writer of The Readout newsletter, and a co-host of "The Readout LOUD" podcast.

Meghana Keshavan

Meghana Keshavan

Biotech Correspondent

Meghana Keshavan covers biotech and contributes to The Readout newsletter.

FDA’s letter to medical device maker iRhythm is a…
FDA’s letter to medical device maker iRhythm is a warning for the industry
This biotech could one day make human eggs from…
This biotech could one day make human eggs from scratch. But first, they’re trying to rethink…
Combination of two drugs can help treat methamphetamine addiction…
Combination of two drugs can help treat methamphetamine addiction for some, new clinical trial data shows 
Regeneron targets obesity, a new microbiome deal, & comparing…
Regeneron targets obesity, a new microbiome deal, & comparing cancer drug costs
Should the feds investigate Aduhelm? Plus: biotech’s biggest binaries…
Should the feds investigate Aduhelm? Plus: biotech’s biggest binaries & regenerating heart tissue
Docs disagree with FDA on Aduhelm, Swiss giants pinch…
Docs disagree with FDA on Aduhelm, Swiss giants pinch pennies, & one SPAC makes it rain

Recommended Stories